Update: ImmunityBio Shares Rise After Completion of Scalable M-ceNK Manufacturing Pathway

MT Newswires Live03-14 02:42

(Updates with the latest stock price movement in the headline and the first paragraph.)

ImmunityBio (IBRX) shares rose more than 8% in Friday trading after the company said it has completed manufacturing engineering programs NK2022 and NK2023, establishing a safe and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer, or M-ceNK, cell therapy platform.

The programs enrolled 64 healthy participants and cancer patients, who completed apheresis collection, the company said, adding that a single apheresis yields up to 5 billion M-ceNK cells good for 8 to 10 therapeutic doses. The collected cells were stored and used for process development and validation, ImmunityBio added.

10 cancer patients received their collected cells following the NK cell enrichment process, with 23 total doses administered. ImmunityBio said the trial demonstrated a successful repeat dosing and cryo-banking of M-ceNK cells, with no serious adverse events.

ImmunityBio also said a phase 1 trial of a combination of M-ceNK with Anktiva, or nogapendekin alfa inbakicept-pmln, in patients with relapsed or refractory tumors has been completed, demonstrating safety following infusion of the M-ceNK drug product.

Price: 8.47, Change: +0.65, Percent Change: +8.25

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619112263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-14 02:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619112263","market":"nz","top_or_hot":-1,"title":"Update: ImmunityBio Shares Rise After Completion of Scalable M-ceNK Manufacturing Pathway","media":"MT Newswires Live","content":"<html><body><p> (Updates with the latest stock price movement in the headline and the first paragraph.)</p><p>ImmunityBio (IBRX) shares rose more than 8% in Friday trading after the company said it has completed manufacturing engineering programs NK2022 and NK2023, establishing a safe and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer, or M-ceNK, cell therapy platform.</p><p>The programs enrolled 64 healthy participants and cancer patients, who completed apheresis collection, the company said, adding that a single apheresis yields up to 5 billion M-ceNK cells good for 8 to 10 therapeutic doses. The collected cells were stored and used for process development and validation, ImmunityBio added.</p><p>10 cancer patients received their collected cells following the NK cell enrichment process, with 23 total doses administered. ImmunityBio said the trial demonstrated a successful repeat dosing and cryo-banking of M-ceNK cells, with no serious adverse events.</p><p>ImmunityBio also said a phase 1 trial of a combination of M-ceNK with Anktiva, or nogapendekin alfa inbakicept-pmln, in patients with relapsed or refractory tumors has been completed, demonstrating safety following infusion of the M-ceNK drug product.</p><p>Price: 8.47, Change: +0.65, Percent Change: +8.25</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Update: ImmunityBio Shares Rise After Completion of Scalable M-ceNK Manufacturing Pathway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpdate: ImmunityBio Shares Rise After Completion of Scalable M-ceNK Manufacturing Pathway\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-14 02:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> (Updates with the latest stock price movement in the headline and the first paragraph.)</p><p>ImmunityBio (IBRX) shares rose more than 8% in Friday trading after the company said it has completed manufacturing engineering programs NK2022 and NK2023, establishing a safe and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer, or M-ceNK, cell therapy platform.</p><p>The programs enrolled 64 healthy participants and cancer patients, who completed apheresis collection, the company said, adding that a single apheresis yields up to 5 billion M-ceNK cells good for 8 to 10 therapeutic doses. The collected cells were stored and used for process development and validation, ImmunityBio added.</p><p>10 cancer patients received their collected cells following the NK cell enrichment process, with 23 total doses administered. ImmunityBio said the trial demonstrated a successful repeat dosing and cryo-banking of M-ceNK cells, with no serious adverse events.</p><p>ImmunityBio also said a phase 1 trial of a combination of M-ceNK with Anktiva, or nogapendekin alfa inbakicept-pmln, in patients with relapsed or refractory tumors has been completed, demonstrating safety following infusion of the M-ceNK drug product.</p><p>Price: 8.47, Change: +0.65, Percent Change: +8.25</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2619112263","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619112263","pubTimestamp":1773427350,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ImmunityBio  shares rose more than 8% in Friday trading after the company said it has completed manufacturing engineering programs NK2022 and NK2023, establishing a safe and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer, or M-ceNK, cell therapy platform.The programs enrolled 64 healthy participants and cancer patients, who completed apheresis collection, the company said, adding that a single apheresis yields up to 5 billion M-ceNK cells good for 8 to 10 therapeutic doses. The collected cells were stored and used for process development and validation, ImmunityBio added.10 cancer patients received their collected cells following the NK cell enrichment process, with 23 total doses administered. ImmunityBio said the trial demonstrated a successful repeat dosing and cryo-banking of M-ceNK cells, with no serious adverse events.ImmunityBio also said a phase 1 trial of a combination of M-ceNK with Anktiva, or nogapendekin alfa inba","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"更新：完成可扩展M-ceNK制造途径后ImmunityBio股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"(Updates with the latest stock price movement in the headline and the first paragraph.)ImmunityBio (IBRX) shares rose more than 8% in Friday trading after the company said it has completed manufacturing engineering programs NK2022 and NK2023, establishing a safe and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer, or M-ceNK, cell therapy platform.The programs enrolled 64 healthy participants and cancer patients, who completed apheresis collection, the company said, adding that a single apheresis yields up to 5 billion M-ceNK cells good for 8 to 10 therapeutic doses. The collected cells were stored and used for process development and validation, ImmunityBio added.10 cancer patients received their collected cells following the NK cell enrichment process, with 23 total doses administered. ImmunityBio said the trial demonstrated a successful repeat dosing and cryo-banking of M-ceNK cells, with no serious adverse events.ImmunityBio also said a phase 1 trial of a combination of M-ceNK with Anktiva, or nogapendekin alfa inbakicept-pmln, in patients with relapsed or refractory tumors has been completed, demonstrating safety following infusion of the M-ceNK drug product.Price: 8.47, Change: +0.65, Percent Change: +8.25","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619112263","isCrawlerRequest":true}